BofA analyst Geoff Meacham raised the firm’s price target on Biogen to $300 from $295 and keeps a Neutral rating on the shares. The company’s estimates for both Q1 EPS and revenue are below consensus, but its 2023 forecasts for revenue and EPS are above the Street. Q1 is seasonally a weaker quarter in Biopharma and for the group generally BofA expects an in-line quarter and for the outlook to be "solid."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BIIB:
- Agios Pharmaceuticals appoints Capello to board of directors
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Biogen price target raised to $320 from $315 at Argus
- Biogen upgraded to Overweight from Neutral at Piper Sandler
- Truist biotechnology analyst to hold an analyst/industry conference call
